141 related articles for article (PubMed ID: 38453100)
21. Pharmacokinetic study of five components of Fuzheng Huayu tablets in healthy human plasma.
Zhang H; Hu Y; Liu X; Li R; Pan Y; Liu C; Yang T
Biomed Chromatogr; 2024 Feb; 38(2):e5782. PubMed ID: 38016814
[TBL] [Abstract][Full Text] [Related]
22. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis.
Wang T; Zhou X; Liu H; Wang J; Zhang P; Zhu Y; Li K; Wei S; Li H; Wang L; Wang R; Zhao Y
Phytother Res; 2018 May; 32(5):757-768. PubMed ID: 29235181
[TBL] [Abstract][Full Text] [Related]
23. Fuzheng Huayu recipe, a traditional Chinese compound herbal medicine, attenuates renal interstitial fibrosis via targeting the miR-21/PTEN/AKT axis.
Wang QL; Tao YY; Xie HD; Liu CH; Liu P
J Integr Med; 2020 Nov; 18(6):505-513. PubMed ID: 32912827
[TBL] [Abstract][Full Text] [Related]
24. The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases.
Chen J; Hu Y; Chen L; Liu W; Mu Y; Liu P
Biomed Pharmacother; 2019 Jun; 114():108846. PubMed ID: 30965233
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological mechanisms of Fuzheng Huayu formula for Aristolochic acid I-induced kidney fibrosis through network pharmacology.
Wang F; Wang S; Wang J; Huang K; Chen G; Peng Y; Liu C; Tao Y
Front Pharmacol; 2022; 13():1056865. PubMed ID: 36569327
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial.
Zhao ZM; Zhu CW; Huang JQ; Li XD; Zhang YX; Liang J; Zhang W; Zhang Y; Jiang XG; Zong YL; Zhang KJ; Sun KW; Zhang B; Lv YH; Xing HC; Xie Q; Liu P; Liu CH
J Ethnopharmacol; 2022 Nov; 298():115599. PubMed ID: 35932973
[TBL] [Abstract][Full Text] [Related]
27. [Mechanism of Fuzheng Huayu Tablets against hepatic fibrosis based on transcriptome and single-cell sequencing].
Lu HG; Peng WX; Jiang LH; Yao Q; Xie X; Lei C; Huang D; Liu JJ
Zhongguo Zhong Yao Za Zhi; 2024 May; 49(10):2597-2606. PubMed ID: 38812160
[TBL] [Abstract][Full Text] [Related]
28. [Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B].
Liu P; Hu YY; Liu C; Xu LM; Liu CH; Sun KW; Hu DC; Yin YK; Zhou XQ; Wan MB; Cai X; Zhang ZQ; Ye J; Tang BZ; He J
Zhong Xi Yi Jie He Xue Bao; 2003 Jul; 1(2):89-98, 102. PubMed ID: 15339577
[TBL] [Abstract][Full Text] [Related]
29. Beneficial Effects of Traditional Chinese Medicine Fuzheng Huayu on the Occurrence of Hepatocellular Carcinoma in Patients with Compensated Chronic Hepatitis B Cirrhosis Receiving Entecavir: A Multicenter Retrospective Cohort Study.
Fan H; Lei S; Zhao Z; Huang Y; Wang H; Liu X; Li X; Xu M; Zhang W; Sun K; Xing H; Mei Y; Huang J; Zhu C; Zhang K; Zong Y; Shen X; Xie Q; Liu C
J Clin Transl Hepatol; 2024 May; 12(5):505-515. PubMed ID: 38779515
[TBL] [Abstract][Full Text] [Related]
30. Active Compounds Derived from Fuzheng Huayu Formula Protect Hepatic Parenchymal Cells from Apoptosis Based on Network Pharmacology and Transcriptomic Analysis.
Wu R; Dong S; Cai FF; Chen XL; Yang MD; Liu P; Su SB
Molecules; 2019 Jan; 24(2):. PubMed ID: 30669350
[TBL] [Abstract][Full Text] [Related]
31. Dynamical Regulation Analysis Identifies Molecular Mechanisms of Fuzheng-Huayu Formula against Hepatitis B-Caused Liver Cirrhosis.
Chen QL; Lu YY; Peng JH; Dong S; Wei B; Song YN; Zhou QM; Zhang H; Liu P; Su SB
Evid Based Complement Alternat Med; 2015; 2015():238495. PubMed ID: 26221171
[TBL] [Abstract][Full Text] [Related]
32. Fuzheng Huayu Formula () prevents rat renal interstitial fibrosis induced by HgCl
Yuan JL; Tao YY; Wang QL; Shen L; Liu CH
Chin J Integr Med; 2017 Aug; 23(8):598-604. PubMed ID: 28197934
[TBL] [Abstract][Full Text] [Related]
33. Fuzheng Huayu Recipe and its active compounds inhibited HBeAg production by promoting TOMM34 gene expression in HBV-infected hepatocytes.
Xing L; Zeng R; Huang K; Xue J; Liu H; Zhao Z; Peng Y; Hu X; Liu C
Front Pharmacol; 2022; 13():907921. PubMed ID: 36249820
[No Abstract] [Full Text] [Related]
34. Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways.
Li XM; Peng JH; Sun ZL; Tian HJ; Duan XH; Liu L; Ma X; Feng Q; Liu P; Hu YY
Acta Pharmacol Sin; 2016 Jun; 37(6):783-93. PubMed ID: 27133300
[TBL] [Abstract][Full Text] [Related]
35. Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice.
Jia YH; Wang RQ; Mi HM; Kong LB; Ren WG; Li WC; Zhao SX; Zhang YG; Wu WJ; Nan YM; Yu J
Lipids Health Dis; 2012 Mar; 11():45. PubMed ID: 22452814
[TBL] [Abstract][Full Text] [Related]
36. Traditional Chinese Medicine Fuzheng Huayu Prevents Development of Liver Fibrosis in Mice.
Jiang C; Iwaisako K; Cong M; Diggle K; Hassanein T; Brenner DA; Kisseleva T
Arch Clin Biomed Res; 2020; 4(5):561-580. PubMed ID: 33210080
[TBL] [Abstract][Full Text] [Related]
37. Chinese medicine CGA formula ameliorates liver fibrosis induced by carbon tetrachloride involving inhibition of hepatic apoptosis in rats.
Tian H; Liu L; Li Z; Liu W; Sun Z; Xu Y; Wang S; Liang C; Hai Y; Feng Q; Zhao Y; Hu Y; Peng J
J Ethnopharmacol; 2019 Mar; 232():227-235. PubMed ID: 30471378
[TBL] [Abstract][Full Text] [Related]
38. Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis.
Liu HL; Lv J; Zhao ZM; Xiong AM; Tan Y; Glenn JS; Tao YY; Weng HL; Liu CH
Sci Rep; 2019 Dec; 9(1):18719. PubMed ID: 31822697
[TBL] [Abstract][Full Text] [Related]
39. Comparative pharmacokinetic and tissue distribution profiles of four major bioactive components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.
Yang T; Liu S; Wang CH; Tao YY; Zhou H; Liu CH
J Pharm Biomed Anal; 2015 Oct; 114():152-8. PubMed ID: 26048667
[TBL] [Abstract][Full Text] [Related]
40. An Herbal Product Alleviates Bleomycin-Induced Pulmonary Fibrosis in Mice via Regulating NF-κB/TNF-α Signaling in Macrophages.
Jing F; Chen X; Xue J; Huang K; Xing F; Hu X; Peng Y; Liu C
Front Pharmacol; 2022; 13():805432. PubMed ID: 35548340
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
